Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.
The speed of technological advancements in the life sciences industry is forcing patent lawyers to consider whether the norms they’re used to dealing with in the profession still apply.
The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.
The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.
Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.
The strongest cannabidiol patent portfolios are owned by Roche, Boehringer Ingelheim, and AbbVie, according to a report released earlier this week.
The European Patent Office has revoked a Bayer-owned patent which covers a type of broccoli adapted to make their harvesting easier.
Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.